Skip to main content
Canna~Fangled Abstracts

Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists’ Discussion Using the Workmat ® Methodology

By September 27, 2021October 17th, 2021No Comments
. 2021 Sep 27;12:722801.

doi: 10.3389/fneur.2021.722801. eCollection 2021.

Oscar Fernandez 1, Lucienne Costa-Frossard 2, Maria Luisa Martínez-Ginés 3, Paloma Montero 4, Jose María Prieto-González 5, Lluís Ramió-Torrentà 6 7 8
Affiliations 

Free PMC article

Abstract

Background: Multiple sclerosis (MS) treatment has radically improved over the last years; however, MS symptom management is still challenging. The novel Spasticity-Plus syndrome was conceptualized to frame several spasticity-related symptoms that can be addressed together with broad-spectrum medication, such as certain cannabinoid-based drugs. The aim of this project was to gain insight into Spanish neurologists’ clinical experience on MS spasticity and associated symptoms, and to assess the acknowledgment and applicability of the Spasticity-Plus syndrome concept in patients with MS.

Methods: Ten online meetings were conducted using the Workmat® methodology to allow structured discussions. Fifty-five Spanish neurologists, experts in MS management, completed and discussed a set of predefined exercises comprising MS symptom assessment and its management in clinical practice, MS symptoms clustering in clinical practice, and their perception of the Spasticity-Plus syndrome concept. This document presents the quantitative and qualitative results of these discussions.

Results: The specialists considered that polytherapy is a common concern in MS and that simplifying the management of MS spasticity and associated manifestations could be useful. They generally agreed that MS spasticity should be diagnosed before moderate or severe forms appear. According to the neurologists’ clinical experience, symptoms commonly associated with MS spasticity included spasms/cramps (100% of the specialists), pain (85%), bladder dysfunction (62%), bowel dysfunction (42%), sleep disorders (42%), and sexual dysfunction (40%). The multiple correspondence analysis revealed two main symptom clusters: spasticity-spasms/cramps-pain, and ataxia-instability-vertigo. Twelve out of 16 symptoms (75%) were scored >7 in a 0-10 QoL impact scale by the specialists, representing a moderate-high impact. The MS specialists considered that pain, spasticity, spasms/cramps, bladder dysfunction, and depression should be a treatment priority given their frequency and chance of therapeutic success. The neurologists agreed on the usefulness of the new Spasticity-Plus syndrome concept to manage spasticity and associated symptoms together, and their experience with treatments targeting the cannabinoid system was satisfactory.

Conclusions: The applicability of the new concept of Spasticity-Plus in MS clinical practice seems possible and may lead to an integrated management of several MS symptoms, thus reducing the treatment burden of disease symptoms.

 

Keywords: cannabidiol (CBD), multiple sclerosis, quality of life, spasticity, symptom management, symptomatic treatment, syndrome, tetrahydrocannabinol (THC)

Conflict of interest statement

The study was funded by an investigational grant from Almirall SA. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors’ views and opinions are not necessarily aligned with those of Almirall SA. OF has received honoraria as consultant in advisory boards, as chair/lecturer in meetings, and from participation in clinical trials and other research projects promoted by Actelion, Allergan, Almirall, Bayer-Schering, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Orizon, Roche, and Teva. LC-F has received honoraria as consultant in advisory boards, travel support, and speaker fees and from participation in clinical trials and other research projects promoted by Almirall, Bayer, Biogen-Idec, Biopas, Bristol Myers Squibb, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. MM-G has received compensation for consulting services and speaking fees and from participation in clinical trials from Almirall, Bayer-Schering, Biogen-Idec, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. PM has received honoraria as consultant in advisory boards, travel support, and speaker fees and from participation in clinical trials and other research projects promoted by Allergan, Almirall, Biogen-Idec, Merck-Serono, Merz, Sanofi-Genzyme and, Teva. JP-G has received honoraria as consultant for Bayer Pharmaceuticals, Biogen Spain S.L., Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Teva Pharmaceutical Industries, Roche Pharma, Almirall Prodesfarma S.A., and Celgene España S.L. JP-G has participated as lecturer/moderator at meetings and/or symposia organized by Almirall Prodesfarma S.A., Bayer Pharmaceuticals, Biogen Spain S.L., Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Teva Pharmaceutical Industries, and Roche Pharma. JP-G has received funding for research projects from Almirall Prodesfarma S.A., Biogen Spain S.L., Novartis Pharmaceutical Corporation, Teva Pharmaceutical Industries, and Sanofi. LR-T has received honoraria as consultant in advisory boards, as chair/lecturer in meetings, and from participation in clinical trials and other research projects promoted by Almirall, Bayer, Biogen-Idec, Sanofi, Genzyme, Merck, Novartis, Roche, Bristol-Myers, and Teva.

Figures

Figure 1

Figure 2

Figure 3

References

    1. Wallin MT, Culpepper WJ. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 GBD 2016 Multiple Sclerosis Collaborators*. Artic Lancet Neurol. (2019) 18:269–85. 10.1016/S1474-4422(18)30443-5 – DOI – PMC – PubMed
    1. Coetzee T, Thompson AJ. Atlas of MS 2020: Informing global policy change. Mult Scler J. (2020) 26:1807–8. 10.1177/1352458520968811 – DOI – PubMed
    1. Pérez-Carmona N, Fernández-Jover E, Sempere ÁP. Epidemiology of multiple sclerosis in Spain. Rev Neurol. (2019) 69:32–8. 10.33588/rn.6901.2018477 – DOI – PubMed
    1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. (2018) 391:1622–36. 10.1016/S0140-6736(18)30481-1 – DOI – PubMed
    1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S. Multiple sclerosis. Nat Rev Dis Prim. (2018) 4:43. 10.1038/s41572-018-0041-4 – DOI – PubMed

LinkOut – more resources

Leave a Reply